GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » EV-to-EBITDA

Kolon Life Science (XKRX:102940) EV-to-EBITDA : -36.99 (As of May. 25, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kolon Life Science's enterprise value is ₩350,802 Mil. Kolon Life Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-9,484 Mil. Therefore, Kolon Life Science's EV-to-EBITDA for today is -36.99.

The historical rank and industry rank for Kolon Life Science's EV-to-EBITDA or its related term are showing as below:

XKRX:102940' s EV-to-EBITDA Range Over the Past 10 Years
Min: -304.22   Med: 25.27   Max: 599.68
Current: -36.99

During the past 13 years, the highest EV-to-EBITDA of Kolon Life Science was 599.68. The lowest was -304.22. And the median was 25.27.

XKRX:102940's EV-to-EBITDA is ranked worse than
100% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.42 vs XKRX:102940: -36.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Kolon Life Science's stock price is ₩21950.00. Kolon Life Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-2683.104. Therefore, Kolon Life Science's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Kolon Life Science EV-to-EBITDA Historical Data

The historical data trend for Kolon Life Science's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science EV-to-EBITDA Chart

Kolon Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.22 -15.95 40.15 21.96 -20.81

Kolon Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.77 186.74 -75.13 -20.81 -27.50

Competitive Comparison of Kolon Life Science's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Kolon Life Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon Life Science's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kolon Life Science's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kolon Life Science's EV-to-EBITDA falls into.



Kolon Life Science EV-to-EBITDA Calculation

Kolon Life Science's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=350802.469/-9483.591
=-36.99

Kolon Life Science's current Enterprise Value is ₩350,802 Mil.
Kolon Life Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-9,484 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science  (XKRX:102940) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kolon Life Science's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21950.00/-2683.104
=At Loss

Kolon Life Science's share price for today is ₩21950.00.
Kolon Life Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-2683.104.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Kolon Life Science EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science (XKRX:102940) Business Description

Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines